Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortOral tablet to reduce COPD flare-ups in chronic bronchitis.Once-daily inhaler that keeps airways open in COPD.
Body systemJoints & ImmunityLungs & Breathing
Drug classPDE4 inhibitorsLong-acting antimuscarinics
SupplyPrescription onlyPrescription onlyWHO essential medicine
Main usesSevere COPD with chronic bronchitis and frequent exacerbationsCOPD maintenance, Severe asthma (add-on)
How it worksReduces airway inflammation by blocking PDE4.Blocks the nerve signal that tightens your airways, for 24 hours.
Starts workingWeeks—
Half-lifeAbout 17 hours5–6 days
Typical adult dose250 micrograms once a day for 4 weeks, then 500 micrograms once a day.Respimat: 2 puffs (5 micrograms) once a day. HandiHaler: 18 micrograms once a day.
FormsTabletSoft mist inhaler, Dry powder capsule inhaler
Common side effectsDiarrhoea, Weight loss, Nausea, Headache, InsomniaDry mouth, Constipation, Cough
Serious side effectsDepression and suicidal thoughts, Anxiety, Reduced appetiteUrinary retention, Acute angle-closure glaucoma (if sprayed in eyes)
Don't take ifModerate to severe liver impairment; Psychiatric disorders (caution); Pregnancy—
AlcoholUsually no problem in moderation. No specific interaction.—
PregnancyUsually avoidedNot recommended in pregnancy.Use with cautionLimited data.
BreastfeedingUsually avoidedAvoid.—
In use since—2002
Brand namesUnited States: DalirespUnited Kingdom: DaxasIndia: Daxas, Roflumilast (generic)United States: Spiriva HandiHaler, Spiriva RespimatUnited Kingdom: Spiriva, BraltusIndia: Tiova
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H—
ATC codeR03DX07R03BB04

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker